Overview

Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Iron deficiency, independent of anemia, appears to increase morbidity and mortality as well as impairing health-related quality of life in chronic heart failure (CHF), and these effects are compounded when patients also experience chronic kidney disease (CKD). This study was designed to determine the effects of intravenous iron treatment on morbidity and mortality following an initial 6-month period and a longer period of up to 5 years.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Aleman
Treatments:
Ferric Compounds
Ferric Oxide, Saccharated
Iron